文献速递免疫规划

中国2008-2013年灭活与减毒活日本脑炎疫苗上市后安全性监测

Post-marketing safety surveillance for inactivated and live-attenuated Japanese encephalitis vaccines in China, 2008-2013.
PubMed 文献 · Vaccine · 2017-05-25

利用中国全国疑似预防接种异常反应信息管理系统2008-2013年数据,评估灭活日本脑炎疫苗(JE-I)和减毒活日本脑炎疫苗(JE-L)的安全性。共报告34,879例AEFI,严重病例361例(1.0%)。2010-2013年JE-L总报告率为214.4/百万剂,JE-I为176.9/百万剂(率比1.2,95%CI 1.1-1.3);JE-I热性惊厥报告信号不平衡,但JE-I与JE-L热性惊厥报告率无显著差异(JE-L 0.3/百万剂 vs JE-I 0.4/百万剂,p=0.05)。

要点

  • 2008-2013年共报告JE-I和JE-L相关AEFI 34,879例,严重病例361例(1.0%)。
  • 2010-2013年JE-L总AEFI报告率214.4/百万剂,JE-I为176.9/百万剂(RR 1.2,95%CI 1.1-1.3)。
  • JE-I热性惊厥报告信号不平衡,但JE-I与JE-L热性惊厥报告率无显著差异(p=0.05)。

核心结论

  • 分析未发现中国JE疫苗存在明显安全性问题,但作者认为进一步研究应考虑JE-I疫苗与热性惊厥,并采用更敏感的方法检测信号。

研究设计与样本

  • 利用中国全国疑似预防接种异常反应信息管理系统2008-2013年数据,检索JE疫苗AEFI报告,以行政数据中的疫苗接种剂次为分母计算并比较粗报告率,并对JE-I与JE-L进行报告不平衡分析以评估潜在安全性信号。

主要发现

  • 共报告JE-I和JE-L相关AEFI 34,879例,男女比1.3:1;严重病例361例(1.0%);13,592例(39.0%)同时接种一种或多种其他疫苗。
  • 2010-2013年JE-L总AEFI报告率214.4/百万剂 vs JE-I 176.9/百万剂(率比1.2,95%CI 1.1-1.3)。
  • JE-I后热性惊厥被发现为报告不平衡信号(SDR)。
  • JE-I与JE-L热性惊厥报告率无显著差异(JE-L 0.3/百万剂 vs JE-I 0.4/百万剂,p=0.05)。

局限性

  • 作者在结论中提出进一步研究应考虑JE-I疫苗与热性惊厥,并采用更敏感的方法检测信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Two types of Japanese encephalitis (JE) vaccines, inactivated JE vaccine (JE-I) and live-attenuated JE vaccine (JE-L), are available and used in China. In particular, one JE-L, produced by a domestic manufacturer in China, was prequalified by WHO in 2013. We assessed the safety of JE vaccines in China during 2008-2013 using the Chinese National Adverse Events Following Immunization Information System (CNAEFIS) data. METHODS: We retrieved AEFI reporting data about JE vaccines from CNAEFIS, 2008-2013, examined demographic characteristics of AEFI cases, and used administrative data on vaccine doses as denominator to calculate and compare crude reporting rates. We also used disproportionality reporting analysis between JE-I and JE-L to assess potential safety signals. RESULTS: A total of 34,879 AEFIs related with JE-I and JE-L were reported, with a ratio of male to female as 1.3:1; 361 (1.0%) cases were classified as serious. JE vaccines were administered concurrently with one or more other vaccines in 13,592 (39.0%) of cases. The overall AEFI reporting rates were 214.4 per million vaccination doses for JE-L and 176.9 for JE-I (rate ratio [RR]: 1.2, 95% confidence interval [CI]: 1.1-1.3) in 2010-2013. Febrile convulsions (FC) following JE-I was found as a signal of disproportionate reporting (SDR). However, there was no significant difference between the reporting rates of FC of JE-I and JE-L (0.3 per million vaccination doses for JE-L, 0.4 for JE-I, p=0.05). CONCLUSIONS: While our analysis did not find apparent safety concern of JE vaccines in China, further study should consider JE-I vaccines and febrile convulsion, and taking more sensitive methods to detect signals.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Wu W, Liu D, Li K, et al. Post-marketing safety surveillance for inactivated and live-attenuated Japanese encephalitis vaccines in China, 2008-2013. Vaccine. 2017. PMID: 28552510. doi:10.1016/j.vaccine.2017.05.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。